North America Orphan Drugs Market by Type (Biological and Non Biological), by Therapeutic (Haematology, Neurology, Oncology, and Others) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

North America Orphan Drugs Market by Type (Biological and Non Biological), by Therapeutic (Haematology, Neurology, Oncology, and Others) and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

ID: 1677 | Pages: 137 | December 2016 | Region: North America


The North America Orphan Drugs Market was worth $34.08 billion in 2016 and estimated to be growing at a CAGR of 7.51%, to reach $48.96 billion by 2021. Orphan drugs are medical products which are utilized for the treatment of ailments or conditions which concern a very small percentage of the population. Diseases that have low occurrence rates are no less important than ones that have a higher frequency.

Orphan drugs are a comparatively niche segment because they are utilized for the treatment of rare diseases. For an ailment that has low frequency, finding the right equilibrium between cost and profit can be a tightrope walk. The total number of illnesses considered as orphan stands at about 7,000 currently, with just about 250 new diseases being added to this list yearly.

The growth of the North America Orphan Drugs market is mainly due to factors such as an increasing healthcare expenditure, favourable government initiatives, growing prevalence of chronic diseases, and small timeline required for orphan drug development. However, factors such as high initial investment, clinical study impediments, and regulatory obstacles are hindering the growth of the market in this region.

The North America Orphan Drugs market is segmented based on Type and Therapeutic. The market for Orphan Drugs, on the basis of Type is segmented into Biological and Non Biological. Non Biological Orphan Drugs lead the market, on the basis of type with more than 60% of the market share. On the basis of Therapeutic, the Orphan Drugs market is segmented into Haematology, Neurology, Oncology, and Others. On the basis of Therapeutics, Neurology accounts for almost 40% of the entire market share.

The North America market has been geographically segmented into US and Canada. Benchmarks for designation of orphan disease differs country to country, in US if the disease is prevalent in fewer than 200,000 people, then it’s termed as a rare disease. The growth of the market in this region is powered by factors such as prolonged market exclusivity and government enticements for orphan medicine.

Presently, the market for orphan drugs represents only about 6% of the complete pharmaceutical market. An extremely conducive environment currently prevails for the growth of the orphan drugs market, thereby encouraging the entry of more companies into the market. The major companies dominating the Orphan Drugs market in this region are Novartis, GlaxoSmithKline, Roche, Alexion, Sanofi, Bristol Myers Squibb, Pfizer, Vertex, Celgene, and Merck.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Type                              

                                5.1.1 Introduction           

                                5.1.2 Biological

                                5.1.3 Non Biological        

                                5.1.4  Y-o-Y Growth Analysis, By Type     

                                5.1.5  Market Attractiveness Analysis, By Type   

                                5.1.6  Market Share Analysis, By Type    

                5.2 Therapeutic                                

                                5.2.1 Haematology         

                                5.2.2 Neurology

                                5.2.3 Oncology 

                                5.2.4 Others      

                                5.2.5  Y-o-Y Growth Analysis, By Therapeutic       

                                5.2.6  Market Attractiveness Analysis, By Therapeutic     

                                5.2.7  Market Share Analysis, By Therapeutic      

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Type

                                                6.1.3.3 By Therapeutic

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Type

                                                6.1.4.3 By Therapeutic

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Type

                                                6.1.5.3 By Therapeutic

                6.2 United States                            

                6.3 Canada                         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Novartis                       

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 GlaxoSmithKline                      

                8.3 Roche                           

                8.4 Alexion                        

                8.5 Sanofi                           

                8.6 Bristol Myers Squibb                              

                8.7 Pfizer                            

                8.8 Vertex                          

                8.9 Celgene                       

                8.10 Merck                        

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. North America Orphan Drugs Market By Type, From 2016-2021 ( USD Billion )
  2. North America Biological Market By Region, From 2016-2021 ( USD Billion )
  3. North America Non Biological Market By Region, From 2016-2021 ( USD Billion )
  4. North America Orphan Drugs Market By Therapeutic, From 2016-2021 ( USD Billion )
  5. North America Haematology Market By Region, From 2016-2021 ( USD Billion )
  6. North America Neurology Market By Region, From 2016-2021 ( USD Billion )
  7. North America Oncology Market By Region, From 2016-2021 ( USD Billion )
  8. North America Other therapeutics Market By Region, From 2016-2021 ( USD Billion )
  9. United States Orphan Drugs Market By Type, From 2016-2021 ( USD Billion )
  10. United States Orphan Drugs Market By Therapeutic, From 2016-2021 ( USD Billion )
  11. Canada Orphan Drugs Market By Type, From 2016-2021 ( USD Billion )
  12. Canada Orphan Drugs Market By Therapeutic, From 2016-2021 ( USD Billion )
Middle East and Africa Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, N...
Latin America Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Gener...
Asia-Pacific Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Genera...
Europe Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Generation s...
North America Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems (CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Gene...
Antacid Market by Submarkets (Chromatography, E-Clinical Trial Solutions, Wireless Health, Clinical Trial Management Systems(CTMS), Healthcare IT outsourcing, Immunoassay, Digital Pathology, Next Generation sequenci...
Middle East and Africa Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous syste...
Latin America Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, ...
Asia-Pacific Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, a...
Europe Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, anti-ca...
North America Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, ...
Generic Drugs Market by type (Biosimilars, simple generic and super generic) by therapeutic drugs (Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, anti-cancer dr...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
502, Kakatiya's Empire,
Jubilee Gardens, Hyderabad,
Telangana, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2017 Market Data Forecast
All Rights Reserved.